San Raffaele
Acute lymphoblastic leukemia treatment cost in Italy is determined by the complexity of therapy and diagnostic protocols. A comprehensive diagnosis of leukemia ranges from $1,800 to $3,500, while specialized procedures like allogenic bone marrow transplantation from a related donor runs from $120,000 to $180,000. Total expenses depend on the leukemia subtype, the number of chemotherapy cycles, and the choice between autologous or allogenic transplants. Patients can expect 30-50% savings compared to the US. Milan and Rome are the primary medical hubs for this treatment.
Typical Acute Lymphoblastic Leukemia Treatment Costs in Italy
Bookimed Expert Insight: Patients requiring advanced cellular therapies find high value at IRCCS-accredited centers like San Raffaele. This facility performed the world's first stem cell therapy for ADA-SCID. For complex cases, Dr. Jacopo Peccatori oversees 90 allogeneic transplants annually. High-volume units in Milan offer better safety for unrelated donor transplants. Professor Fabio Ciceri provides expert coordination for integrated gene and cell therapy protocols.
| إيطاليا | تركيا | إسبانيا | |
| زرع نخاع العظم | من $95,000 | من $36,000 | من $71,782 |
| زراعة نخاع العظم الذاتي | من $90,000 | من $31,500 | من $40,000 |
| زراعة النخاع العظمي من متبرع قريب | من $120,000 | من $65,000 | من $13,935 |
| زراعة النخاع العظمي من متبرع غير قريب | من $150,000 | من $80,000 | من $150,000 |
| العلاج الكيميائي لسرطان الثدي | من $4,500 | من $1,200 | من $3,500 |
Bookimed لا يضيف رسوماً إضافية على أسعار علاج سرطان الدم الليمفاوي الحاد. الأسعار مأخوذة من قوائم الأسعار الرسمية للعيادات. تدفع مباشرة في العيادة مقابل علاجك عند وصولك إلى البلد.
Bookimed ملتزم بسلامتك. نحن نعمل فقط مع المؤسسات الطبية التي تحافظ على معايير دولية عالية في علاج سرطان الدم الليمفاوي الحاد ولديها التراخيص اللازمة لخدمة المرضى الدوليين في جميع أنحاء العالم.
Bookimed يقدم مساعدة خبراء مجانية. منسق طبي شخصي يدعمك قبل وأثناء وبعد العلاج، ويحل أي مشاكل. لن تكون وحيداً أبداً في رحلة علاج سرطان الدم الليمفاوي الحاد.
رئيس أحد أكبر أقسام زراعة نخاع العظم في إيطاليا - يشرف الدكتور بيكاتوري على أكثر من 90 عملية زراعة خيفية سنوياً في سان رافاييل.
يقود البروفيسور فابيو سيسيري تجارب رائدة في العلاج الخلوي والجيني لسرطان الدم الليمفاوي الحاد في مستشفى سان رافاييل.
Top-rated Italian hospitals for Acute Lymphoblastic Leukemia include San Raffaele in Milan and Ospedale Pediatrico Bambino Gesù in Rome. These IRCCS-accredited centers specialize in bone marrow transplants, CAR T-cell therapy, and advanced gene research. Most elite facilities maintain Newsweek rankings for oncology and hematology excellence.
Bookimed Expert Insight: San Raffaele handles over 52,000 operations annually and operates one of Europe largest research hubs. Data shows Dr. Jacopo Peccatori leads 90 allogeneic transplants every year. Choosing an IRCCS-accredited hospital ensures your treatment plan directly incorporates the latest clinical research and gene therapy breakthroughs.
Patient Consensus: Patients emphasize choosing high-volume centers that manage induction, consolidation, and transplants in one facility. They note that clear communication regarding risk stratification and emergency protocols is essential for managing complex leukemia care.
Italy coordinates leukemia care through a centralized integrated framework led by the GIMEMA Foundation. This system links 150 specialized hematology centers to ensure standardized clinical protocols nationwide. Treatment relies on a hub-and-spoke model where complex procedures like stem cell transplants occur at major research hospitals.
Bookimed Expert Insight: Data shows that Italy's most successful outcomes are linked to high-volume units like San Raffaele in Milan. Dr. Jacopo Peccatori at San Raffaele performs 90 allogeneic transplants annually. This volume is significant because surgical experience directly correlates with better survival. Patients should target clinics with IRCCS accreditation, which signifies elite research status recognized by the Italian Ministry of Health.
Patient Consensus: Patients note that care is highly concentrated in large university hospitals where coordination is smoother. They emphasize that while local labs can perform routine checks, major treatment decisions should remain with these specialized central teams.
Italy treats acute lymphoblastic leukemia (ALL) using risk-adapted protocols managed by specialized national cooperative groups. Pediatric patients follow the AIEOP-BFM regimen, while adults are treated under GIMEMA guidelines. These standardized protocols ensure patients receive evidence-based care across accredited Italian hematology centers.
Bookimed Expert Insight: Italian centers like San Raffaele bridge the gap between research and clinical practice through IRCCS accreditation. Professor Fabio Ciceri and Dr. Jacopo Peccatori lead a unit performing 90 allogeneic transplants annually. This high volume is a key quality signal for complex leukemia cases. Patients should prioritize centers with dedicated bone marrow transplant units for post-induction care.
Patient Consensus: Patients note that care is highly center-based and structured into induction, consolidation, and maintenance phases. They often emphasize that treatment plans are frequently adjusted based on early MRD testing results rather than following a rigid, one-size-fits-all schedule.
Italy provides advanced targeted therapies and CAR T-cell therapies for acute lymphoblastic leukemia at specialized centers. The Italian Medicines Agency (AIFA) regulates these immunotherapies. Treatments like Kymriah and Yescarta are available. Highly specialized hospitals like IRCCS Ospedale San Raffaele perform these complex procedures.
Bookimed Expert Insight: San Raffaele in Milan stands out because it combines high surgical volume with deep research roots. The hospital performs over 52,000 operations annually. Dr. Jacopo Peccatori manages one of Italy's largest transplant units. They handle 90 allogeneic transplants yearly from related and unrelated donors. This high volume often translates to smoother clinical pathways for complex cellular therapies.
Patient Consensus: Patients note that while these treatments exist, access is centralized in major cities like Milan and Rome. They emphasize the importance of securing a specialist referral to a transplant-capable hospital early in the process.